Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
28Bio
South San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
28Bio is a pre-clinical stage biotechnology company focused on developing next-generation therapies for autoimmune and inflammatory diseases by leveraging the biology of regulatory T cells (Tregs). The company utilizes advanced protein engineering and cell biology to create treatments that precisely modulate the immune system to restore homeostasis and promote tissue repair. Founded by world-renowned protein engineer K. Christopher Garcia and former NIH leader Sonia Skarlatos, 28Bio aims to overcome the limitations of broad immunosuppression through targeted immune regulation. The company is currently operating in stealth mode and is backed by prominent life science investors, including Westlake Village BioPartners.
- Therapeutic areas
- EndocrinologyImmunologyNeurology
- Modalities
- Cell therapyT cell therapyProteinRecombinant protein
- Industry
- Biotech
Beyond the preview
Go deeper on 28Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 28Bio.